- Supported exchanges /
- F /
- 2B30.F
XERIS BIOPH.HOL. DL-0001 (2B30 F) stock market data APIs
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
XERIS BIOPH.HOL. DL-0001 Financial Data Overview
2.898 | |
2.898 | |
- | |
2.898 | |
2.898 | |
1.36-2.96 | |
432 M | |
149 M | |
181 M | |
1.31 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
XERIS BIOPH.HOL. DL-0001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 181 M
- EBITDA -24 999 000
- Earnings Per Share -0.39
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get XERIS BIOPH.HOL. DL-0001 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get XERIS BIOPH.HOL. DL-0001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: